The potential rescheduling of cannabis to Schedule III has been met with a mix of celebration and skepticism within the industry. While many view this as a significant step forward, I find myself in the camp of cautious observers. As someone who has closely followed and written about cannabis policy, I’ve long maintained that Schedule III is less about progress and more about creating a sweet spot for Big Pharma to dominate the cannabis market, leaving smaller players and consumers at a disadvantage.
A closer look at the past, present, and future of that tiny thing at the…
According to the National Survey on Drug Use and Health (NSDUH), past-year cannabis use among…
These days, cannabis has successfully permeated almost every field of medicine. This reflects the scientific…
By High Times Staff, with reporting and photography by Brett Churchill The Berkeley stop of…
The legal weed business taught customers to chase the next deal, and independent dispensaries are…
Cannabis doesn’t give you talent you don’t already have. A psychiatrist specializing in cannabis and…